Almac’s New Discovery Group Likely to Work with Sister Array-Based Dx Firm | GenomeWeb
Almac Group, a Northern Ireland-based pharmaceutical-services company that operates a variety of businesses, including Almac Diagnostics, which sells array-based research tools and tests, announced this week the creation of a new business unit called Almac Discovery.
According to the company, Almac Discovery will focus exclusively on developing approaches to treat cancer and associated conditions, with the goal of developing a biomarker or diagnostic in parallel with each potential new therapeutic.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.